Parameters | Survivor | Non-survivor | Overall population | P |
---|---|---|---|---|
Number | 38 | 16 | 54 | NA |
Age (years) | 49 (45–56) | 50 (45–61) | 49 (45–56) | 0.458 |
Male, n (%) | 31 (81.6%) | 12 (75%) | 43 (79.6%) | 0.714 |
WBC (10^9/L) | 14.22 (12.43–15.77) | 14.85 (13.68–17.45) | 14.23 (13.09–16.44) | 0.0709 |
LC (10^9/L) | 0.89 (0.75–1.05) | 0.77 (0.66–0.90) | 0.86 (0.71–1.03) | 0.0316 |
SOFA score | 7 (6–9) | 10 (9–13) | 8 (6–10) | <0.0001 |
SAPS II | 28 (24–34) | 43 (31–50) | 31 (25–42) | 0.0011 |
APACHE II score | 14 (12–16) | 19 (16–22) | 15 (13–19) | 0.0005 |
CRP (mg/L) | 124.5 (101.1–148.3) | 137.3 (117.4–175.2) | 126.9 (105.7–157.1) | 0.076 |
IgM (g/L) | 0.85 (0.78–1.01) | 0.73 (0.63–0.91) | 0.84 (0.75–0.95) | 0.0067 |
IL-6 (pg/ml) | 80 (68–91.08) | 93.01 (81.01–100.9) | 83.13 (72.8–94.26) | 0.0114 |
IL-10 (pg/ml) | 83.72 (70.76–97.9) | 94.44 (80.86–104.4) | 87.6 (75.33–100.6) | 0.1093 |
CD100+/CD4+ T cells % | 66.4 (54.9–75.6) | 53.9 (46.4–65.5) | 61.8 (50.1–71.5) | 0.0174 |
CD100+/CD8+ T cells % | 73.3 (63.1–77.9) | 54.4 (48.9–69) | 70.8 (56.2–76.3) | 0.0003 |
CD72+/CD19+ B cells % | 68.4 (59.1–74.5) | 54.9 (46–66.4) | 65.8 (55.6–73.2) | 0.0018 |